Biotech stocks to watch at #SITC17
The Society for Immunotherapy of Cancer's (SITC) 32nd Annual meeting from November 8-12, 2017. There will be resources for patient, clinician and researcher to explore. As for investors, there will many biotech company with abstracts presentations to watch.
For late-breaking abstracts investors should keep their "I" (pun intended) on watch these three biotech under $10.00: Infinity Pharmaceuticals Inc (INFI:NASDAQ) from on going trial IPI-549, Iovance Biotherapeutics Inc (IOVA:NASDAQ) with six abstracts to be presented, for late-breaking title: Novel cryopreserved tumor infiltrating lymphoctyes (LN-144). Inovia Pharmaceuticals Inc (INO:NASDAQ) for MEDI0457 their phase 1/2 HPV-associated squamous cell carcinoma of the head & neck. For completed listed late-breaking abstracts titles on the conference website at http://ir.lbio.com/phoenix.zhtml?c=254507&p=RssLanding&cat=news&id=2306129
Additional abstracts are from Cellular Therapy biotechnology stocks has been making a run like: Juno Therapeutics Inc (JUNO:NASDAQ), Sangamo Therapeutics Inc (SGMO:NASDAQ), Gilead Sciences Inc (GILD:NASDAQ). Listed on the conference webiste http://www.sitcancer.org/2017/abstracts/titles
Here are more biotech stocks to watch next week: Bristol-Myers Squibb Co (BMY:NYSE), Calithera Biosciences Inc (CALA:NASDAQ), Five Prime Therapeutics Inc (FPRX:NASDAQ), Incyte Corp (INCY:NASDAQ0, NewLink Genetics Corp (NLNK:NASDAQ), and Trillium Therapeutics Inc (TRIL:NASDAQ). For more details on conference webiste https://www.sitcancer.org/2017/abstracts/titles